A US district court decided this week that the lawsuit challenging the legality and constitutionality of BRCA gene patents owned by the University of Utah and exclusively licensed to Myriad has sufficient merit to be heard.
On-Q-ity is developing a cancer diagnostic platform that combines monitoring DNA repair biomarkers to predict treatment response and microfluidic chips that enable the capture, enumeration, and characterization of circulating tumor cells in a patient's bloodstream.
The licensing of technology by universities to companies added as much as $187 billion to the US gross national product and $457 billion to US gross industrial output, and created nearly 300,000 new jobs from 1996 to 2007, according to the report.
The patent, No. 4354633, is entitled "Hypoxia-Regulated Genes," and claims various aspects of the RTP801 gene, including inhibitors targeting either the mRNA or peptide products of the gene, Quark said.